Advances in Combined Therapy for Soft Tissue Sarcomas

Submission Deadline: 01 August 2025 View: 38 Submit to Special Issue

Guest Editors

Prof. Dr. Mateusz Spałek

Email: mateusz@spalek.co   

Affiliation:

1. Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, W.K. Roentgena 5 Street, 02-781 Warsaw, Poland

2. Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, W.K. Roentgena 5 Street, 02-781 Warsaw, Poland

Homepage:

Research Interests: Soft tissue sarcoma; bone tumors; bone metastases; melanoma; skin cancer; SBRT; hypofractionation

Dr. Siyer Roohani

Email: siyer.roohani@charite.de

Affiliation:

1. Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

2. BIH Charité Junior Clinician Scientist Program, BIH Biomedical Innovation Academy, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany

3. German Cancer Consortium (DKTK), Partner site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany

Homepage:

Research Interests: Cancer biology; cell culture; cancer biomarkers

Dr. André N. Abrunhosa-Branquinho

Email: andre.branquinho@chln.min-saude.pt; andre.branquinho@ulsssm.min-saude.pt

Affiliation: Department of Radiotherapy, Unidade Local Saúde Santa Maria, 1649-028 Lisboa, Portugal

Homepage:

Research Interests: Radiotherapy; oncology; conformal radiotherapy; radiation therapy; gastrointestinal cancer; skin cancer; radiation oncology

Summary

Soft tissue sarcomas (STS) are a diverse group of cancers that originate in the connective tissues. Treatment has traditionally involved surgery, radiotherapy, and chemotherapy, but outcomes have varied due to the complexity and rarity of these tumors. Recent advancements have focused on combined therapies to improve survival rates and reduce recurrence. These include integrating targeted therapies and immunotherapies with conventional approaches, which has shown promise in enhancing treatment precision and effectiveness. Additionally, molecular profiling has enabled more personalized treatment, guiding the selection of drugs that target specific genetic mutations in tumors. The use of preoperative and intraoperative radiation, along with limb-sparing surgical techniques, has also contributed to reducing the need for amputation and preserving function. Overall, these advancements in combined therapy approaches are improving patient outcomes and offering new hope for those with STS. 

Keywords